Teleflex (TFX)
(Delayed Data from NYSE)
$200.45 USD
-1.07 (-0.53%)
Updated May 8, 2024 04:00 PM ET
After-Market: $200.58 +0.13 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Average Brokerage Rating
Current ABR | 2.36 |
ABR (Last week) | 2.36 |
# of Recs in ABR | 14 |
Average Target Price | $247.75 |
LT Growth Rate | 7.50% |
Industry | Medical - Instruments |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | 3.35 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | Needham & Company | Michael Matson | Hold | Hold |
5/3/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/3/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
5/2/2024 | Piper Sandler | Matthew O'Brien | Hold | Hold |
5/2/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
2/23/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
2/23/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1/16/2024 | Stephens | George Sellers | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.